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The members of the regulatory factor (RF) gene family, Na1/H1 exchanger (NHE)-RF and NHE3 kinase A
regulatory factor (E3KARP) are necessary for cAMP to
inhibit the epithelial brush border NHE isoform 3
(NHE3). The mechanism of their action was studied using PS120 fibroblasts stably transfected with rabbit
NHE3 and wild type rabbit NHE-RF or wild type human
E3KARP. 8-Bromo-cAMP (8-Br-cAMP) had no effect on
Na1/H1 exchange activity in cells expressing NHE3
alone. In contrast, in cells co-expressing NHE-RF, 8-BrcAMP inhibited NHE3 by 39%. In vivo phosphorylation
of NHE3 demonstrated that cAMP increased phosphorylation in two chymotrypsin-generated phosphopeptides of NHE3 in cells containing NHE-RF or E3KARP
but not in cells lacking these proteins. The requirement
for phosphorylation of NHE-RF in this cAMP-induced
inhibition of NHE3 was examined by studying a mutant
NHE-RF in which serines 287, 289, and 290 were mutated
to alanines. Wild type NHE-RF was a phosphorylated
protein under basal conditions, but treatment with 8-BrcAMP did not alter its phosphorylation. Mutant NHE-RF
was not phosphorylated either under basal conditions
or after 8-Br-cAMP. 8-Br-cAMP inhibited NHE3 similarly
in PS120/NHE3 cells containing wild type or mutant
NHE-RF. NHE-RF and NHE3 co-precipitated and did so
similarly with and without cAMP. Mutant NHE-RF also
similarly immunoprecipitated NHE3 in the presence
and absence of 8-Br-cAMP. This study shows that members of the regulatory factor gene family, NHE-RF and
E3KARP, are necessary for cAMP inhibition of NHE3 by
allowing NHE3 to be phosphorylated. This inhibition is
not dependent on the phosphorylation of NHE-RF.

It is now established that cAMP-dependent inhibition of
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NHE3,1 the epithelial brush border isoform Na1/H1 exchanger, requires the presence of associated regulatory proteins of the regulatory factor (RF) gene family (1– 8). There are
two identified members of this family, Na1/H1 exchanger regulatory factor (NHE-RF) and NHE3 kinase A regulatory protein (E3KARP) (1). Recent reports have suggested a model
whereby NHE-RF, in association with PKA II and ezrin, functions as a signaling complex to regulate NHE3 activity (2,
9 –12). Multiple aspects of this model have not been explicitly
studied, although an increase in phosphorylation of NHE3 is
necessary for the cAMP inhibition (4). The present experiments
use PS120 fibroblasts stably expressing vesicular stomatitis
virus glycoprotein (VSVG)-tagged NHE3 and either native
NHE-RF or E3KARP or a mutant form of NHE-RF to study two
phosphorylation-related aspects of the proposed signaling complex model through which cAMP inhibits NHE3. First, the
mechanism by which cAMP regulates NHE3 activity was examined. Specifically, the question of whether NHE-RF or
E3KARP is necessary for PKA to phosphorylate NHE3 was
addressed. Second, although NHE-RF was originally isolated
and characterized as a PKA substrate (7), recent in vivo experiments indicate that NHE-RF exists as a phosphoprotein in
unstimulated human embryonic kidney (HEK293) cells and
OK cells but that treatment of these cells with cAMP increased
the phosphorylation of NHE-RF minimally or not at all (5, 7, 8).
These prior in vivo studies, however, did not specifically correlate the relation between the effect of cAMP on NHE3 transporter activity and the phosphorylation state of NHE-RF. Accordingly, the functional and biochemical properties of a
nonphosphorylated mutant NHE-RF containing serine to alanine mutations of residues 287, 289, and 290 (NHE-RF/S287A/
S289A/S290A) was examined. The results confirmed that in
PS120 cells expressing NHE3, there is an absolute requirement
for the presence of NHE-RF or E3KARP for cAMP to inhibit
transporter activity. These studies showed that NHE-RF or
E3KARP is required for PKA-mediated phosphorylation of
NHE3. On the other hand, phosphorylation of NHE-RF is not
required for it to function as a co-factor in cAMP-mediated
inhibition of NHE3.
MATERIALS AND METHODS

Cell Culture Models—Studies were performed using PS120/NHE3V
fibroblasts, which lack endogenous NHE-RF or E3KARP (1). These are
1
The abbreviations used are: NHE3, Na1/H1 exchanger isoform 3;
NHE-RF, Na1/H1 exchanger regulatory factor; E3KARP, NHE3 kinase
A regulatory factor; RF, regulatory factor; PKA, protein kinase A; OK,
opossum kidney; 8-Br-cAMP, 8-bromo-cAMP; VSVG, vesicular stomatitis virus glycoprotein; MES, 4-morpholineethanesulfonic acid; PAGE,
polyacrylamide gel electrophoresis.
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PS120 cells stably transfected with rabbit NHE3 tagged at its C terminus with an epitope derived from the VSVG, as described previously
(13). Wild type and mutated NHE-RF and wild type E3KARP cDNAs
were cloned into the pECE vector. PS120/NHE3V fibroblasts were
co-transfected using Lipofectin (Life Technologies, Inc.) with the pECE/
NHE-RF or E3KARP constructs and pPlo2 to permit selection by hygromycin (1). Cells resistant to 600 unit/ml hygromycin were selected
through eight passages prior to the study. Transfected PS120 fibroblasts were maintained at 37 °C in a humidified atmosphere with 5%
CO2 in Dulbecco’s modified Eagle’s medium supplemented with 10%
(v/v) fetal calf serum, penicillin (100 units/ml), and streptomycin (100
mg/ml).
The mutant form of NHE-RF was made using the MORPHTM mutagenesis kit (5 Prime 3 3 Prime, Inc., Boulder, CO), and the mutation
was confirmed by double-stranded sequencing (8). Serine residues 287,
289, and 290 were mutated to alanine residues using an oligonucleotide
of the following sequence: 59-GCTGGTGTCAGCGGCGGCGGCTCTTGC-39. Reverse transcription polymerase chain reaction was used to
confirm successful transfections.
Na1/H1 Exchange—Na1/H1 exchange activity was determined in
cells seeded on glass coverslips using the pH-sensitive fluorescent dye
29,79-bis(carboxyethyl)-5– 6-carboxyfluorescein, NH4Cl prepulse, and a
computerized fluorometer, as described (2, 14). The cells were serumdeprived for 12–20 h prior to study. The NH4Cl pulse was targeted to
achieve an initial pHi of 6.0, and only cells with initial pHi values
between 6.0 and 6.2 were included for analysis. Na1/H1 exchange
activity, expressed as DpHi/min, was calculated from the slope of the
initial 10 –15 s of sodium-dependent pHi recovery. Over this time period, the relation between pHi and time approximated a linear function.
When studied, cells were pretreated with 100 mM 8-Br-cAMP during the
final 15 min of the dye loading and continuously during the perfusion.
At the end of each experiment, the cells were equilibrated in pH clamp
media containing 20 mM HEPES, 20 mM MES, 110 mM KCl, 14 mM
NaCl, 1 mM MgSO4, 1 mM CaCl2, 1 mM TMA, 25 mM glucose, and 10 mM
nigericin at pH 6.1 and 7.2. All measurements in control and experimental cells were made on cells from the same passage and assayed on
the same day.
In Vivo Phosphorylation of NHE3—To determine the in vivo phosphorylation of NHE3, cells were washed with phosphate-free Dulbecco’s
modified Eagle’s medium and labeled in vivo for 4 h using the same
medium containing 2.5 mCi of [32P]orthophosphate. At the end of the
incubation, half of the cells were treated with 100 mM 8-Br-cAMP for 15
min. Control and cAMP-treated cells were scraped and resuspended in
500 ml of a solution containing 60 mM HEPES/Tris, pH 7.4, 150 mM
NaCl, 3 mM KCl, 25 mM sodium pyrophosphate, 5 mM EDTA, 5 mM
EGTA, 1 mM Na3VO4, 50 mM NaF, and protease inhibitors (0.1 mM
phenylmethylsulfonyl fluoride, 1 mM phenanthroline, and 1 mM iodoacetamide) (IP buffer). Cells were collected by centrifugation for 10 min at
12,000 3 g in an Eppendorf centrifuge and resuspended in IP buffer
containing 1% Triton X-100 (IPT buffer), lysed by being drawn through
a 23 gauge needle, and agitated on a rotating rocker at 4 °C for 30 min,
followed by centrifugation at 12,000 3 g for 30 min. The supernatants
were first precleared with protein A-Sepharose 6M beads by rocking for
1 h. The beads were then spun down, and the supernatants were
incubated overnight with 5 ml of anti-VSVG polyclonal antibody. Protein A-Sepharose beads previously treated with PS120 cell extract
solubilized by 1% Triton X-100 were then added and allowed to rock for
an additional 2 h. The beads were eluted by boiling in 70 ml of Laemmli
SDS sample buffer. The phosphoprotein corresponding to NHE3 was
identified on 10% SDS-polyacrylamide gels and autoradiography. For
two-dimensional mapping, NHE3 was excised from the gels and washed
in 10% methanol and 5% glacial acetic acid, followed by a wash in 50%
methanol. The gel pieces were incubated with 100 mg of L-1-tosylamide2-phenylethyl chloromethyl ketone-treated chymotrypsin in 0.4
NH4HCO3 at 37 °C overnight, followed by a second, 8-h chymotrypsin
digestion. The digested peptides were separated on thin layer chromatography plates, as described (5).
In Vitro Back-phosphorylation of NHE3—To extend these experiments, an in vitro “back-phosphorylation” assay was employed to assess
PKA-mediated phosphorylation of NHE3. The rationale for this approach is based on the evidence that PKA phosphorylates a specific
serine residue(s) in the C terminus of NHE3 (4). These sites should be
available in vitro to be phosphorylated in NHE3 immunoprecipitated
from untreated cells but not in cells treated with cAMP, in which they
are occupied by an unlabeled phosphate residue. PS120 cells expressing
VSVG-tagged NHE3 alone or in the presence of native or mutant
NHE-RF were studied under basal conditions or after treatment of the
cells with 100 mM 8-Br-cAMP for 15 min. The immunoprecipitation

procedures were performed as indicated above using protein A-Sepharose beads. Samples were eluted with 100 ml of 30 mM glycine HCl, pH
2.8, and immediately neutralized with the addition of 10 ml of 1 M Tris,
pH 11. Samples were phosphorylated at pH 7.4 for 10 min at 30 °C in
the presence of 21 mM glycine, 100 mM Tris, pH 7.4, 50 mM MgCl2, 180
units of the catalytic subunit of PKA (Promega), and 50 mCi of
[g-32P]ATP.
The reaction was terminated by boiling in Laemmli buffer and run on
10% SDS-PAGE gel. The proteins were transferred to nitrocellulose,
and the phosphoproteins were visualized by autoradiography. After
autoradiography, Western immunoblotting using polyclonal anti-VSVG
antibodies was performed to assess sample loading of the gels, and the
immune complexes were detected by ECL (Amersham Pharmacia Biotech). The autoradiographs and Western immunoblots were quantitated using laser densitometry with ImageQuant software.
In Vivo Phosphorylation of NHE-RF—Methods similar to those described above were employed to determine the in vivo phosphorylation
of NHE-RF. In vivo phosphorylated NHE-RF was immunoprecipitated
from [32P]orthophospate-labeled cells that had not been treated or had
been treated with 100 mM 8-Br-cAMP, using a polyclonal antibody to
recombinant full-length NHE-RF, which we had previously described
(8). Antibody was conjugated to protein A-Sepharose beads using cyanogen bromide (8). The beads were then incubated overnight with the
32
P-labeled cell lysates and recovered by centrifugation. The beads were
washed three times in lysis buffer, after which 100 ml of SDS-sample
buffer was added, and the samples were heated to 85 °C for 10 min. The
proteins were resolved on 6% polyacrylamide slab gels, which separated
NHE-RF from IgG.
Co-immunoprecipitation—Co-immunoprecipitation experiments were
performed using cell lysates from PS120 cells expressing NHE3V and
either wild type or mutant NHE-RF in the absence or presence of 8-BrcAMP. The lysates were split, and proteins were immunoprecipitated
either using an anti-VSVG antibody or the anti-NHE-RF antibody. The
individual antibodies were conjugated to protein A-Sepharose beads using
cyanogen bromide. NHE3 and NHE-RF were resolved on 10 and 6%
polyacrylamide gels, respectively.
Representative autoradiographs and Western immunoblots are
shown. Statistical analysis of the Na1/H1 exchange transport rates and
phosphorylation of specific phosphopeptides between control and experimental samples was performed using Student’s t test for paired data.
RESULTS

cAMP Inhibition and Phosphorylation of NHE3 Require
NHE-RF—PS120 cells transfected with NHE3V and rabbit
NHE-RF were used to correlate the physiologic effect of cAMP
to inhibit Na1/H1 exchange with the phosphorylation state of
NHE3. Western immunoblot analysis on whole cell lysates
using anti-VSVG antibody and a polyclonal antibody to fulllength recombinant NHE-RF demonstrated that expression of
NHE3V was similar in all cell lines and that expression of
NHE-RF was approximately equal in the cell lines expressing it
(data not shown). Na1/H1 exchange activity is expressed as
sodium-dependent pHi recovery following acidification of the
cells. The rate of recovery was calculated in a restricted range
of pHi and over a time course that approximated an initial rate.
The results are summarized in Table I. In PS120/NHE3V cells
not co-transfected with NHE-RF, cAMP did not significantly
inhibit NHE3. In contrast, cAMP inhibited NHE3 in cells
transfected with wild type rabbit NHE-RF, the pHi recovery
decreasing from a rate of 1.78 6 0.17 DpHi/min in the absence
of cAMP to 1.09 6 0.17 in the presence of cAMP (n 5 6, p ,
0.01).
To determine the effect of 8-Br-cAMP on NHE3 phosphorylation, [32P]orthophosphate loaded cells were exposed to 100 mM
8-Br-cAMP for 15 min. NHE3 phosphorylation was not significantly different in the absence or presence of 8-Br-cAMP incubation in cells lacking NHE-RF and E3KARP or in the cells
with either NHE-RF or E3KARP based on one-dimensional
SDS-PAGE (data not shown).
Fig. 1A shows the two-dimensional chymotrypsin digestion
phosphopeptide maps of NHE3V. In control PS120/NHE3V
cells, phosphorylation of NHE3 produced a pattern with five
well defined phosphopeptides (Fig. 1A, 1–5). cAMP did not alter
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TABLE I
The effect of cAMP on Na1/H1 exchanger activity in PS120/NHE3V cells
Summary of the effect of 100 mM 8-Br-cAMP on Na1/H1 exchange activity as determined by the initial rate of sodium-dependent pHi recovery
using 29,79-bis(carboxyethyl)5– 6-carboxyfluorescein fluorescence. PS120 cells stably expressing rabbit NHE3 were co-transfected with either wild
type rabbit NHE-RF or rabbit NHE-RF with serine to alanine mutations at residues 287, 289, and 290. Results are reported as DpHi/min and
expressed as means 6 S.E. n refers to number of separate experiments.
NHE-RF

Control

cAMP

Inhibition

None (n 5 6)
Wild type (n 5 6)
Mutant S287A/S289A/S290A (n 5 6)

2.22 6 0.30
1.78 6 0.17
1.82 6 0.11

2.10 6 0.20
1.09 6 0.17a
1.12 6 0.03a

2.5 6 5.6
39.2 6 6.2
37.0 6 4.8

%

a

P , 0.01 (control vs. cAMP).

FIG. 1. NHE-RF and E3KARP are necessary for 8-Br-cAMP-induced phosphorylation of NHE3. A, two-dimensional phosphopeptide
map of in vivo phosphorylated NHE3V in the absence and presence of 8-Br-cAMP. Control PS120/NHE3V and PS120/NHE3V cells stably
transfected with E3KARP or NHE-RF were incubated with [32P]orthophosphate for 4 h and treated with 100 mM 8-Br-cAMP for 15 min. NHE3V
was immunoprecipitated and treated with chymotrypsin, as described under “Materials and Methods.” The peptides were separated by electrophoresis and thin layer chromatography and visualized by autoradiography. A representative experiment is shown; similar results were found in
a second identical experiment. B, quantification of the signal from individual phosphopeptides of chymotrypsin-digested NHE3V. The signals from
individual phosphopeptides in A and a second identical experiment were quantified by densitometry and averages are shown. To eliminate
variations in total radioactivity in each sample, the intensity of each phosphopeptide on a given TLC plate was normalized to the intensity of
phosphopeptide 2, which did not change in phosphorylation in the control/cAMP conditions.

the phosphopeptide map of NHE3V in control cells (Fig. 1A). In
contrast, 8-Br-cAMP increased the phosphorylation of two
phosphopeptides of NHE3 (Fig. 1A, 3 and 4, arrowheads) in
cells that contained either NHE-RF or E3KARP (Fig. 1A).
These results were quantitated in two experiments. The total
counts of the IP NHE3 was initially determined by Cerenkov
counting, and equal counts were used for the control/cAMP
conditions. By analysis of the total counts in the area of the five

specific phosphopeptides, the control/cAMP conditions were
further normalized with the result that similar total counts
were examined for each set of control/cAMP conditions. Visual
inspection of the five phosphopeptides revealed that one phosphopeptide, phosphopeptide 2, was most consistent in magnitude of phosphorylation in the control/cAMP conditions for
control cells, as well as for NHE-RF- and E3KARP-transfected
cells. Consequently, phosphopeptide 2 was used to further nor-
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malize the data by comparing the number of counts in each
phosphopeptide on a given plate to that in phosphopeptide 2 on
the same plate, which was set to 100%. With this normalization, in two experiments phosphopeptides 3 and 4 increased in
the presence of cAMP in the NHE-RF- and E3KARP-transfected cells, but in the untransfected cells, these phosphopeptides increased less or not at all. Phosphopeptide 1 did not have
consistent changes with cAMP in NHE-RF- and E3KARPtransfected cells, whereas phosphopeptide 5 decreased in control cells, as well as in NHE-RF- and E3KARP-transfected
cells. In Fig. 1B, we show the changes in each phosphopeptide
normalized to phosphopeptide 2 on each plate. Assuming that
the changes in phosphorylation of phosphopeptides 3 and 4
caused by cAMP in NHE-RF- and E3KARP-transfected cells
were acting by the same mechanisms, we calculated the significance of the cAMP effect on phosphopeptides 3 and 4 using the
effects in NHE-RF- and E3KARP-transfected cells as separate
experiments. The difference in changes caused by cAMP between NHE-RF/E3KARP-transfected cells compared with in
untreated cells for phosphopeptide 3 was 0.14 6 0.03, p ,
0.025, and for phosphopeptide 4 was 0.21 6 0.05, p , 0.025.
Confirmatory evidence that cAMP increased NHE3 phosphorylation was provided by in vitro back-phosphorylation of
NHE3 studied in control conditions and when cells were exposed in vivo to 8-Br-cAMP before the in vitro phosphorylation
with the catalytic subunit of protein kinase A. In PS120/
NHE3V control cells not containing NHE-RF, there was no
difference in PKA-induced in vitro phosphorylation of NHE3V
in the presence versus in the absence of cAMP in vivo (21.2 6
8.1%, n 5 5, ns) (Fig. 2). In contrast, in cells stably expressing
NHE-RF and mutant NHE-RF, PKA caused significantly less
phosphorylation of NHE3V in vitro in cells exposed in vivo to
cAMP (259.4 6 8.9%, n 5 5, p , 0.005, and 265.0 6 15.1%, n 5
5, p , 0.05, respectively).
cAMP Inhibition of NHE3 Does Not Require NHE-RF Phosphorylation—Further studies evaluated the role of phosphorylation of NHE-RF in the cAMP inhibition of NHE3. Studies
were performed only with NHE-RF, because previous studies
showed that E3KARP was not phosphorylated under basal
conditions or with 8-Br-cAMP exposure (2). PS120/NHE3V
cells stably transfected with wild type NHE-RF or NHE-RF/
S287AS289A/S290A or not transfected with NHE-RF were
metabolically labeled in vivo with [32P]orthophosphate and
then exposed to 8-Br-cAMP for 15 min. NHE-RF was then
immunoprecipitated and separated by SDS-PAGE, and autoradiography and Western analysis were performed on the same
samples (Fig. 3). NHE-RF (Fig. 3, left) but not the mutant
NHE-RF (Fig. 3, right) was phosphorylated under basal conditions in cells that were not exposed to 8-Br-cAMP. 8-Br-cAMP
exposure did not significantly alter the phosphorylation of
NHE-RF (Fig. 3, left). There was a 16 6 11% increase in
NHE-RF phosphorylation in cAMP-treated cells (n 5 3, p 5 not
significantly different). As shown in Fig. 3, right, cAMP did not
cause phosphorylation of the mutant NHE-RF.
It was next determined whether mutant NHE-RF was sufficient to allow cAMP to inhibit NHE3 even though mutant
NHE-RF was not phosphorylated under basal conditions or in
response to cAMP. In Table I, it is shown that 8-Br-cAMP
inhibited NHE3 in PS120 cells transfected with mutant NHERF. These cells had a rate of intracellular pH recovery of 1.82 6
0.11 DpHi/min in the absence of cAMP and 1.12 6 0.03 in the
presence of cAMP (n 5 6, p , 0.01). The percentage of inhibition of NHE3 rate caused by cAMP was similar in cells transfected with wild type NHE-RF and mutant NHE-RF (Table I).
NHE3 and NHE-RF Co-Precipitation Is Not Dependent on
NHE-RF Phosphorylation or Altered by cAMP Treatment—We

FIG. 2. 8-Br-cAMP alters NHE3 phosphorylation in the presence of NHE-RF and mutant NHE-RF. A, representative autoradiographs (upper panels) and Western immunoblots (lower panels) of the
effect of in vivo 8-Br-cAMP exposure on the in vitro phosphorylation of
immunoprecipitated NHE3. NHE3 was immunoprecipitated from
PS120 cells expressing VSVG-tagged NHE3 in the absence (no NHERF) and in the presence of co-expression of either wild type NHE-RF
(NHE-RF) or NHE-RF/S287A/S289A/S290A (mutant NHE-RF). The
cells were studied in the absence of 8-Br-cAMP (2) or following 15 min
in vivo treatment with 100 mM 8-Br-cAMP (1). The immunoprecipitated
NHE3 was then phosphorylated in vitro using PKA catalytic subunit
and [g-32P]ATP. A representative experiment is shown; similar results
were found in five identical experiments. B, results from the five above
experiments were analyzed by scanning densitometry/ImageQuant
software. The effect of in vivo cAMP exposure on in vitro PKA-induced
phosphorylation was determined as percentage of change in NHE3
phosphorylation. Results shown are mean 6 S.E. of cAMP effect (paired
t test).

previously demonstrated that immunoprecipitation of NHE-RF
co-precipitated NHE3. We now show that NHE-RF and NHE3
co-precipitate and that similar co-precipitation occurs in the
absence and presence of 8-Br-cAMP (Fig. 4). In addition, when
similar experiments were performed with PS120/NHE3V cells
stably expressing mutant NHE-RF, mutant NHE-RF and
NHE3 co-precipitated. This co-precipitation was similar in control and 8-Br-cAMP-treated cells (Fig. 5).
DISCUSSION

cAMP regulation of the intestinal epithelial brush border
Na1/H1 exchanger NHE3 occurs physiologically as part of the
digestive process, and it occurs in an exaggerated form in
diarrheal diseases, such as cholera. Similarly, parathyroid hormone inhibition of renal proximal tubule NHE3 is partially
mediated by cAMP (15). Prior studies have shown a requirement in this regulation for members of the regulatory factor
gene family NHE-RF or E3KARP. A mechanism suggested as
being involved in RF mediation of cAMP inhibition of NHE3
includes action in a signaling complex that includes NHE3,
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FIG. 3. 8-Br-cAMP does not alter NHE-RF phosphorylation or
cause phosphorylation of a mutant NHE-RF. Representative autoradiograph (top) and Western immunoblot (bottom) of NHE-RF immunoprecipitated from [32P]orthophosphate-labeled PS120 cells expressing rabbit NHE3V and wild type NHE-RF (left panel) or NHE3V
and NHE-RF/S287A/S289A/S290A (right panel). Studies were performed in the absence (2cAMP) and presence (1cAMP) of 100 mM
8-Br-cAMP. The bands representing NHE-RF are at 55 kDa. Similar
results were found in three identical experiments.

FIG. 4. NHE-RF co-precipitates NHE3: lack of effect of cAMP.
Representative Western immunoblot demonstrating co-immunoprecipitation of native rabbit NHE-RF and NHE3. PS120 cells were co-transfected with rabbit NHE3V and rabbit NHE-RF. Studies were performed
in the absence of cAMP (left) or the presence of cAMP (right). NHE3 (87
kDa) was resolved using 10% PAGE (top), and NHE-RF (55 kDa) was
resolved using 6% PAGE (bottom). Similar results were found in three
identical experiments.

NHE-RF or E3KARP, ezrin, and cAMP-dependent protein kinase II and results in cAMP-dependent phosphorylation of
NHE3 (2, 9 –12, 16). Previous results indicate that NHE-RF or
E3KARP binds to ezrin and to NHE3. Although neither
NHE-RF nor E3KARP acts as an A kinase-anchoring protein,
ezrin does bind PKA II (2, 15). However, until the current
study, it was not established that cAMP-dependent phosphorylation of NHE3 required the presence of NHE-RF or E3
KARP. The current studies were designed to more fully understand the biochemical steps between the activation of PKA and
inhibition of NHE3 activity, specifically to determine (i)
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FIG. 5. Mutant NHE-RF co-precipitates NHE3: lack of cAMP
effect. Representative Western immunoblot demonstrating co-immunoprecipitation of mutant rabbit NHE-RF and NHE3. PS120 cells were
co-transfected with rabbit NHE3V and rabbit mutant NHE-RF containing serine to alanine mutations at residues 287, 289, and 290. Studies
were performed in the absence (left) or presence (right) of cAMP. NHE3
was resolved using 10% PAGE (top), and NHE-RF was resolved using
6% PAGE (bottom). Similar results were found in two identical
experiments.

whether NHE-RF or E3KARP was necessary for cAMP to phosphorylate NHE3; and (ii) whether basal or cAMP-stimulated
phosphorylation of NHE-RF was important for cAMP inhibition of NHE3 or for NHE-RF to associate with NHE3 as part of
a signaling complex.
The present studies confirm our previous observation that
the presence of NHE-RF or E3KARP is necessary for cAMP
inhibition of NHE3 (1) and show that NHE-RF or E3KARP is
necessary for cAMP to phosphorylate NHE3. Using two-dimensional thin layer chromatographic analysis of chymotryptic
digests of in vivo [32P]orthophosphate-labeled NHE3, these
studies show that cAMP did not change the NHE3 phosphorylation pattern in the absence of NHE-RF or E3KARP, whereas
a change in two chymotryptic phosphopeptides of NHE3 occurred with cAMP treatment in cells transfected with NHE-RF
or E3KARP. In addition, it was shown that cAMP caused
changes in the same phosphopeptides in cells containing either
NHE-RF or E3KARP. Collectively, these studies demonstrate
that in PS120 cells expressing rabbit NHE3, there is an absolute requirement for NHE-RF or E3KARP to demonstrate
cAMP inhibition of NHE3, that NHE3 and NHE-RF physically
associate in vivo, and that NHE-RF or E3KARP is required for
PKA-mediated phosphorylation of NHE3.
Others have demonstrated that cAMP causes changes in
phosphorylation of NHE3 expressed in fibroblasts or the OK
renal proximal tubule cell line (17–19). However, there is some
controversy concerning which part of NHE3 is phosphorylated
and the significance of the phosphorylation for cAMP inhibition
of NHE3. Kurashima et al. (17) demonstrated that in AP-1
fibroblasts, cAMP phosphorylates NHE3 on a single serine
residue, Ser605. Mutating this serine inhibited cAMP inhibition
of NHE3 by 50%. More recently, Zhao et al. (19), in studies
using the same AP-1 cells as well as OK cells, showed that
cAMP phosphorylates NHE3 on multiple serines. In addition,
mutating either Ser605 or Ser552, greatly decreased cAMP inhibition of NHE3. Mutating three serines other than Ser605 and
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Ser552 also decreased cAMP inhibition of NHE3, an effect potentially due to a larger change in the structure of NHE3 (19).
Our results cannot be directly compared with those of Zhao et
al. (19) or Kurashima et al. (17), because different proteases
were used. However, our results are most consistent with the
studies of Zhao et al. (19), because cAMP increased phosphorylation of more than one phosphopeptide in NHE3. Importantly, the data most inconsistent among previous studies of
NHE3 phosphorylation relate to the potential role for Ser552 in
cAMP inhibition of NHE3. Cabado et al. (20) used C-terminal
truncation mutants of NHE3 to define the domain in the NHE3
cytoplasmic C terminus, which is involved in cAMP inhibition
of NHE3 in AP-1 cells. C-terminal truncation to NHE3 amino
acid 638 decreased the extent of cAMP inhibition, whereas
truncation to amino acid 579 eliminated cAMP regulation of
NHE3. On face value, these results are consistent with Ser605
but not Ser552 being involved in cAMP inhibition because
Ser552 is N-terminal of the domain of NHE3, which is involved
in cAMP regulation of NHE3.
The second major aim of the present experiments was to
study the relationship between the phosphorylation of
NHE-RF and its function in cAMP inhibition of NHE3. Prior in
vitro experiments using chemically purified, immunopurified,
and recombinant NHE-RF have indicated that NHE-RF was
phosphorylated by PKA (2, 4 – 8). On the other hand, more
recent studies using HEK293 and OK cells expressing rabbit
NHE-RF have indicated that although NHE-RF is a phosphoprotein in unstimulated cells, treatment of the cells with cAMP
resulted in little (HEK293) or no (OK cells) increase in phosphorylation of NHE-RF (2). The relation between the in vivo
phosphorylation status of NHE-RF and PKA regulation of
Na1/H1 exchange activity, however, was not determined in
those experiments. The present experiments using PS120 cells
support the observation that cAMP does not significantly increase the phosphorylation of wild type NHE-RF. These results
also indicate that an increase by PKA in NHE-RF phosphorylation is not critical to its function as a co-factor in PKA regulation of NHE3. Although the failure to observe an increase in
the phosphorylation of NHE-RF following treatment with
cAMP of PS120 cells confirms the findings from studies using
HEK293 and OK cells, it remained possible that cAMP phosphorylation of NHE-RF was masked by virtue of the fact that
NHE-RF was overexpressed in all three model cell systems.
However, this consideration was eliminated by the finding that
the S287A/S289A/S290A mutant was not constitutively phosphorylated in vivo, nor was its phosphorylation state altered by
cAMP, yet the mutant nonphosphorylated form of NHE-RF
co-immunoprecipitated NHE3 and was fully active as an accessory co-factor for PKA-mediated inhibition of NHE3. Moreover,
mutant NHE-RF facilitated phosphorylation of NHE3, based
on back-phosphorylation studies. Collectively, these findings
provide strong confirmation for the conclusion that basal or
PKA-mediated phosphorylation of NHE-RF is not essential to
its function in regulating the relationship between PKA activation and NHE3 activity and NHE3 phosphorylation in PS120
cells or in the physical association between NHE-RF and
NHE3.
Several points are worthy of additional discussion. First, the
present results indicate that one or more of the NHE-RF serine
residues 287, 289, or 290 is phosphorylated in the basal state.
At the present time, the functional significance of the basal
phosphorylation of NHE-RF is unknown, and the relevant protein kinase has not been identified. Although the phosphorylation of NHE-RF by PKA is not critical to its interaction with
NHE3, it remains possible that the phosphorylation of
NHE-RF is necessary and required for some of its other phys-

iologic functions, such as those related to its binding to the b2
receptor or to CFTR (12, 21). Another issue relates to differences in these in vivo findings and previously reported in vitro
studies of cAMP inhibition of Na1/H1 exchange based on reconstitution of renal brush border vesicles. In these in vitro
studies, PKA phosphorylation of NHE-RF appeared to occur
and to be necessary for NHE-RF to act as a co-factor in PKAmediated inhibition of rabbit renal brush border Na1/H1 exchange activity (4 – 8). In addition, in vitro studies using a
recombinant protein of NHE-RF/S287A/S289A/S290A and a
brush border reconstitution assay indicated that the mutant
was not a substrate for PKA but that it also was not functional
in mediating an inhibitory effect of PKA on renal brush border
Na1/H1 exchange (8). At the present time, there is no clear
explanation for these differences between the in vitro and in
vivo studies. One potentially relevant difference relates to the
study of native rabbit BBM NHE3 from renal epithelial cells
versus the study of NHE3 transfected into a fibroblast cell line.
It may be speculated that if the phosphorylation of NHE-RF by
PKA is not critical to its function in allowing PKA phosphorylation of NHE3, basal or cAMP-stimulated NHE-RF phosphorylation might be required to activate or deactivate an additional factor in rabbit solubilized renal brush border
membranes; this postulated factor would not be involved in
PS120 cells. The more difficult nature of the in vitro reconstitution studies must be considered as an additional explanation
for these differences.
In summary, the present experiments indicate that NHE-RF
or E3KARP is absolutely required for NHE3 inhibition by
cAMP when expressed in PS120 cells. NHE-RF and NHE3 are
physically associated in these cells, and NHE-RF or E3KARP
allows PKA-mediated phosphorylation of NHE3.
Acknowledgment—We thank Dr. Stephen Dahl (Department of Medicine, Division of Nephrology, The Johns Hopkins University School of
Medicine) for helpful discussions during these experiments.
REFERENCES
1. Yun, C. H., Oh, S., Zizak, M., Steplock, D., Tsao, S., Tse, C.-M., Weinman, E. J.,
and Donowitz, M. (1997) Proc. Natl. Acad. Sci. U. S. A. 99, 3010 –3015
2. Lamprecht, G., Weinman, E. J., and Yun, C.-H. C. (1998) J. Biol Chem. 273,
29972–29978
3. Weinman, E. J., Dubinsky, W. P., and Shenolikar, S. (1988) J. Membr. Biol.
101, 11–18
4. Weinman, E. J., Dubinsky, W. P., Dinh, Q., Steplock, D., and Shenolikar, S.
(1989) J. Membr. Biol. 109, 233–241
5. Weinman, E. J., Steplock, D., Bui, G., Yuan, N., and Shenolikar, S. (1990)
Am. J. Physiol. 258, F1254 –F1258
6. Weinman, E. J., Steplock, D., and Shenolikar, S. (1993) J. Clin. Invest. 92,
1781–1786
7. Weinman, E. J., Steplock, D., and Shenolikar, S. (1995) J. Clin. Invest. 95,
2143–2149
8. Weinman, E. J., Steplock, D., Tate, K., Hall, R. A., Spurney, R. F., and
Shenolikar, S. (1998) J. Clin. Invest. 101, 2199 –2206
9. Reczek, D., Berryman, M., and Bretscher, A. (1997) Cell Biol. 139, 169 –179
10. Reczek, D., and Bretscher, A. (1998) J. Biol. Chem. 273, 18452–18458
11. Donowitz, M., Khurana, S., Tse, C.-M., and Yun, C. H. (1998) Am. J. Physiol.
274, G971–G977
12. Hall, R. A., Premont, R. T., Chow, C. W., Blitzer, J. T., Pitcher, J. A., Claing,
A., Stoffel, R. H., Barak, L. S., Shenolikar, S., Weinman, E. J., Grinstein, S.,
and Lefkowitz, R. J. (1998) Nature 392, 626 – 630
13. Hoogerwerf, W. A., Tsao, S. C., Devuyst, O., Levine, S. A., Yun, C. H., Yip,
J. W., Cohen, M. E., Wilson, P. D., Lazenby, A. J., Tse, C.-M., and Donowitz,
M. (1996) Am. J. Physiol. 270, G29 –G41
14. Levine, S. A., Montrose, M. H., Tse, C.-M., and Donowitz, M. (1993) J. Biol.
Chem. 268, 25527–25535
15. Azarani, A., Goltzman, D., and Orlowski, J. (1995) J. Biol. Chem. 270,
20004 –20010
16. Dransfield, D. T., Bradford, A. J., Smith, J., Martin, M., Roy, C., Mangeat,
P. H., and Goldenring, J. R. (1997) EMBO J. 2, 35– 43
17. Kurashima, K., Yu, F. H., Cabado, A. G., Szabó, E. Z., Grinstein, S., and
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